#1 Clinical Trials Search in Europe

TALADEGIB

TALADEGIB (also known as LY2940680 or ENV-101) is an investigational drug currently being studied in various clinical trials for treating advanced cancers and idiopathic pulmonary fibrosis (IPF). As a potent Hedgehog (Hh) pathway inhibitor, TALADEGIB works by blocking specific enzymes that cancer cells need to grow and divide. Clinical trials are evaluating TALADEGIB both alone and in combination with other anticancer agents to determine its safety, effectiveness, and optimal dosing. These studies involve patients with various types of advanced solid tumors, including those with specific genetic mutations, as well as patients with lung conditions like IPF. This article provides an overview of the current clinical research involving TALADEGIB.

Table of Contents

What is Taladegib?

Taladegib (also known as LY2940680 or ENV-101) is an investigational anti-cancer medication that belongs to a class of drugs called Hedgehog pathway inhibitors [1]. It is being studied for the treatment of various types of cancer and other conditions such as idiopathic pulmonary fibrosis. Taladegib is not yet approved by regulatory agencies for regular clinical use but is being evaluated in multiple clinical trials to assess its safety and effectiveness.

Taladegib is administered orally in the form of tablets or capsules, which makes it convenient for patients as it doesn’t require hospital visits for intravenous administration [2]. The medication is currently only available to patients participating in clinical trials.

How Taladegib Works

Taladegib works by targeting and inhibiting a specific cellular pathway called the Hedgehog (Hh) signaling pathway [3]. This pathway plays an important role in embryonic development but can become abnormally activated in certain cancers, contributing to tumor growth.

More specifically, taladegib is a potent inhibitor of a protein called Smoothened (Smo), which is a key component of the Hedgehog pathway. By blocking Smoothened, taladegib prevents the activation of Gli1, a transcription factor that, when activated, turns on genes involved in cell growth and survival [4]. Scientists can measure the level of Gli1 inhibition in skin biopsies to determine if taladegib is effectively blocking the Hedgehog pathway in patients.

In certain cancers, especially those with mutations in a gene called PTCH1 (Patched-1), the Hedgehog pathway becomes continuously activated. PTCH1 normally functions as a negative regulator of the pathway, and when it has loss-of-function mutations, the pathway becomes overactive, potentially contributing to cancer development [4]. Taladegib may be particularly effective in cancers with these specific genetic alterations.

Conditions Treated with Taladegib

Based on clinical trials data, taladegib is being investigated for several medical conditions:

Cancer Types

  • Advanced Solid Tumors: Taladegib is being studied in patients with various types of advanced solid tumors, particularly those with specific genetic mutations in the PTCH1 gene [4].
  • Basal Cell Carcinoma (BCC): This is a type of skin cancer where the Hedgehog pathway is often abnormally activated [1].
  • Medulloblastoma: A type of brain cancer that occurs mainly in children and sometimes involves Hedgehog pathway activation [5].
  • Rhabdomyosarcoma: A type of cancer that develops from skeletal muscle cells, most common in children [5].
  • Small Cell Lung Cancer: Taladegib has been studied in combination with chemotherapy drugs (carboplatin and etoposide) for this aggressive form of lung cancer [6].
  • Esophageal and Gastroesophageal Junction Adenocarcinoma: Taladegib is being investigated in combination with chemotherapy and radiation therapy for these cancers [7].

Non-Cancer Conditions

  • Idiopathic Pulmonary Fibrosis (IPF): This is a chronic, progressive lung disease characterized by scarring of lung tissue. Taladegib is being evaluated for its potential to help patients with IPF [8].

Dosage and Administration

As taladegib is still in clinical trials, the optimal dosage has not been definitively established. However, from the clinical trials data, several dosage regimens have been studied:

  • For advanced solid tumors: Doses ranging from 50 mg to 600 mg once daily have been studied, with 200 mg and 300 mg once daily being common doses in recent trials [1][4].
  • For idiopathic pulmonary fibrosis: A dose of 200 mg once daily has been studied [8].
  • For pediatric cancers: Dosages based on body surface area have been used, ranging from 23 mg/m² to 370 mg/m² once daily [5].

Taladegib is taken orally, typically once daily, with treatment cycles usually lasting 28 days. In some clinical trials, taladegib is administered in combination with other cancer treatments such as chemotherapy or radiation therapy [7].

Clinical Studies of Taladegib

Taladegib has been evaluated in multiple clinical trials to assess its safety, effectiveness, and proper dosing:

Phase 1 Studies

Initial studies focused on determining the safety, tolerability, and proper dosage of taladegib in patients with advanced cancers. These studies found that taladegib could be administered at doses up to 600 mg daily, with the most common side effects being manageable [1].

A study in Japanese patients with advanced solid tumors evaluated doses of 100 mg, 200 mg, and 400 mg daily and found that taladegib was generally well-tolerated in this population [3].

Another study investigated how taladegib is processed by the body (pharmacokinetics) in healthy volunteers, finding that most of the drug is eliminated through feces [9].

Phase 2 Studies

More recent studies have focused on specific patient populations:

  • A study is evaluating taladegib at doses of 200 mg and 300 mg once daily in patients with advanced solid tumors that have specific mutations in the PTCH1 gene [4].
  • Another study is assessing taladegib at a dose of 200 mg once daily in patients with idiopathic pulmonary fibrosis [8].
  • Taladegib is also being studied in combination with other cancer treatments, such as chemotherapy and radiation therapy, for esophageal and gastroesophageal junction cancers [7].

Pediatric Studies

A study specifically focused on children with medulloblastoma or rhabdomyosarcoma that has returned or doesn’t respond to initial treatment is evaluating taladegib at various dosages based on body surface area [5].

Potential Side Effects

While taladegib is still being studied and the full profile of side effects is not completely characterized, some potential side effects have been observed in clinical trials:

  • Hair loss (alopecia): This is a common side effect of Hedgehog pathway inhibitors [1].
  • Fatigue: Feeling tired or exhausted is commonly reported [1].
  • Gastrointestinal symptoms: These may include nausea, vomiting, constipation, or diarrhea [6].
  • Decreased appetite: Some patients experience reduced desire to eat [6].
  • Liver enzyme elevations: Temporary increases in liver enzymes have been observed in some patients [6].
  • Blood count changes: These may include decreases in certain types of blood cells, which could potentially increase the risk of infection, bleeding, or fatigue [6].

The severity and frequency of these side effects may depend on the dose of taladegib, whether it’s used alone or in combination with other treatments, and individual patient factors [8].

Drug Interactions

Limited information is available about potential drug interactions with taladegib as it is still in clinical development. However, some studies have specifically examined potential interactions:

  • A study is investigating the potential interaction between taladegib and nintedanib (a medication used to treat idiopathic pulmonary fibrosis) [10].
  • Another study evaluated the effects of food and a proton pump inhibitor (a type of medication that reduces stomach acid) on how taladegib is absorbed by the body [2].
  • Taladegib has also been studied in combination with other cancer drugs, including LY3039478 (a Notch inhibitor), suggesting these medications can be used together [11].

As with any medication, it’s important for patients in clinical trials to inform their healthcare providers about all medications, supplements, and herbal products they are taking to avoid potential harmful interactions.

Ongoing Research and Future Directions

Research on taladegib continues to evolve, with several ongoing clinical trials exploring its potential in different conditions and in combination with other treatments:

  • A Phase 2 study is evaluating taladegib in patients with advanced solid tumors that have specific mutations in the PTCH1 gene, which may help identify which patients are most likely to benefit from this treatment [4].
  • Taladegib is being investigated for idiopathic pulmonary fibrosis, which represents a potential expansion beyond cancer treatment [8].
  • Studies are exploring taladegib in combination with chemotherapy and radiation therapy for various cancers, which may enhance its effectiveness [7].
  • Research is ongoing to better understand how taladegib interacts with other medications, which will help guide its safe use if it receives regulatory approval [10].

The results of these ongoing studies will provide more information about the safety and effectiveness of taladegib and help determine which patients are most likely to benefit from this treatment.

If you are interested in learning more about taladegib or are considering participating in a clinical trial, it’s important to discuss this with your healthcare provider, who can provide personalized information based on your specific medical condition and circumstances.

Clinical Trial Aspect Details
Drug Names TALADEGIB (also known as LY2940680, ENV-101)
Mechanism of Action Hedgehog (Hh) pathway inhibitor that blocks the smoothened (Smo) protein
Conditions Studied – Advanced solid tumors
– Solid tumors with PTCH1 loss-of-function mutations
– Small cell lung carcinoma
– Idiopathic pulmonary fibrosis (IPF)
– Medulloblastoma in children
– Rhabdomyosarcoma
– Esophageal and gastroesophageal junction adenocarcinoma
Dosage Ranges – Adults: 50-600 mg orally once daily
– Children: Doses based on body surface area (up to 370 mg/m²)
– Most common adult doses tested: 100 mg, 200 mg, 300 mg, 400 mg
Administration Oral tablets or capsules taken once daily
Combination Therapies – With carboplatin and etoposide for small cell lung cancer
– With paclitaxel, carboplatin, and radiation for esophageal cancer
– With LY3039478 (another cancer drug)
– Interaction studies with nintedanib for IPF
Primary Outcomes Measured – Maximum tolerated dose (MTD)
– Safety profile and adverse events
– Objective response rate (ORR)
– Progression-free survival (PFS)
– Changes in lung function for IPF studies
Secondary Measurements – Pharmacokinetics (Cmax, Tmax, AUC)
– Clinical benefit rate (CBR)
– Overall survival (OS)
– Duration of response (DOR)
– Gli1 inhibition (marker of drug activity)
– Patient-reported outcomes for IPF
Safety Monitoring – Non-hematological toxicities
– Hematological toxicities
– Vital signs
– Laboratory abnormalities
– Hospitalizations
Trial Phases Phase 1, Phase 1b, Phase 2 trials (no Phase 3 trials reported)
Special Populations – Adults with advanced cancers
– Pediatric patients with medulloblastoma or rhabdomyosarcoma
– Japanese patients with advanced cancers
– Patients with IPF

FAQ

  • What is TALADEGIB and how does it work? TALADEGIB (also known as LY2940680 or ENV-101) is an investigational drug that acts as a Hedgehog (Hh) pathway inhibitor. It works by blocking the smoothened (Smo) protein, which is part of the Hedgehog signaling pathway that regulates cell growth and division. By inhibiting this pathway, TALADEGIB may stop or slow the growth of cancer cells. It's being studied for various types of advanced cancers and conditions like idiopathic pulmonary fibrosis (IPF).
  • What types of cancer is TALADEGIB being tested for? TALADEGIB is currently being tested in clinical trials for several types of advanced cancers. These include solid tumors with PTCH1 loss-of-function mutations, small cell lung cancer, esophageal adenocarcinoma, gastroesophageal junction cancer, medulloblastoma in children, rhabdomyosarcoma, and various other advanced or metastatic solid tumors. It's being studied both as a single agent and in combination with other cancer treatments.
  • What are the common dosages of TALADEGIB used in clinical trials? In clinical trials, TALADEGIB has been tested at various doses ranging from 50 mg to 600 mg taken orally once daily. For example, one study evaluated doses of 100 mg, 200 mg, 300 mg, 400 mg, and 600 mg. Another study specifically compared 200 mg versus 300 mg daily doses. For children, doses were calculated based on body surface area (up to 370 mg/m²). The optimal dose depends on the specific condition being treated and whether TALADEGIB is used alone or in combination with other medications.
  • What side effects have been monitored in TALADEGIB clinical trials? Clinical trials of TALADEGIB monitor various side effects including both non-hematological toxicities (like nausea, vomiting, constipation, diarrhea, fatigue, and liver enzyme elevations) and hematological toxicities (like decreased blood cell counts that might cause thrombocytopenia or neutropenia). Researchers also track vital signs (pulse, blood pressure, respiration rate, temperature), blood oxygen levels, and laboratory abnormalities. The severity of these effects is carefully documented to determine the drug's safety profile and appropriate dosing.
  • Besides cancer, what other conditions is TALADEGIB being studied for? Beyond cancer, TALADEGIB is being studied for idiopathic pulmonary fibrosis (IPF), a serious lung disease characterized by progressive scarring of lung tissue. A Phase 2 clinical trial is evaluating the safety and efficacy of TALADEGIB at a 200 mg daily dose for 12 weeks in patients with mild to moderate IPF. The study is measuring changes in lung function tests like forced vital capacity (FVC) and diffusing capacity (DLCO), as well as patient-reported outcomes regarding shortness of breath.

Ongoing Clinical Trials on TALADEGIB

  • Study on the Safety and Effectiveness of Taladegib for Patients with Idiopathic Pulmonary Fibrosis

    Not recruiting

    1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium France Germany Ireland Italy

Glossary

  • Hedgehog (Hh) pathway: A signaling pathway in cells that regulates cell growth and differentiation. It plays an important role during embryonic development but abnormal activation of this pathway can lead to cancer. TALADEGIB works by inhibiting this pathway.
  • Smoothened (Smo): A protein that is part of the Hedgehog signaling pathway. TALADEGIB is a Smo antagonist, meaning it blocks this protein's function, which helps inhibit the Hedgehog pathway that can drive cancer growth.
  • PTCH1: Patched-1 gene that normally acts as a tumor suppressor by inhibiting the Hedgehog pathway. Loss-of-function mutations in PTCH1 can lead to abnormal activation of the pathway and cancer development. Some TALADEGIB trials specifically target cancers with these mutations.
  • Loss of Function (LOF) mutations: Genetic changes that result in a gene product that doesn't function properly or is not produced at all. In the case of PTCH1, LOF mutations can lead to uncontrolled cell growth and cancer.
  • Gli1: A protein that acts as a marker for Hedgehog pathway activity. Clinical trials measure Gli1 levels to determine if TALADEGIB is effectively inhibiting the Hedgehog pathway.
  • Maximum Tolerated Dose (MTD): The highest dose of a drug that doesn't cause unacceptable side effects. Finding the MTD is often a key goal of Phase 1 clinical trials.
  • Dose-Limiting Toxicity (DLT): Side effects that are severe enough to prevent increasing the dose of a drug in a clinical trial. DLTs help determine the maximum tolerated dose.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and excreted. PK parameters measured in TALADEGIB trials include Cmax (maximum concentration) and AUC (area under the curve).
  • Area Under the Curve (AUC): A measure of the total exposure to a drug over time. It's calculated from the concentration-time curve and is an important pharmacokinetic parameter.
  • Cmax: Maximum observed drug concentration in the blood after administration. This is one of the pharmacokinetic parameters measured in TALADEGIB clinical trials.
  • Tmax: Time to reach maximum drug concentration in the blood. This helps understand how quickly the drug is absorbed.
  • Objective Response Rate (ORR): The percentage of patients whose cancer shrinks or disappears after treatment. ORR includes both complete responses (CR) and partial responses (PR).
  • Complete Response (CR): The disappearance of all target lesions (tumors) in response to treatment.
  • Partial Response (PR): A decrease of at least 30% in the sum of diameters of target lesions (tumors) in response to treatment.
  • Stable Disease (SD): Cancer that is neither growing nor shrinking significantly. It's considered a form of disease control, though not as favorable as CR or PR.
  • Clinical Benefit Rate (CBR): The percentage of patients who achieve complete response, partial response, or stable disease. It's a broader measure of treatment effectiveness than ORR.
  • Progression Free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it getting worse.
  • Overall Survival (OS): The length of time from either the date of diagnosis or the start of treatment that patients are still alive.
  • Duration of Response (DOR): The time from first documented response to disease progression.
  • Idiopathic Pulmonary Fibrosis (IPF): A chronic, progressive lung disease characterized by scarring of lung tissue. TALADEGIB is being studied as a potential treatment for this condition.
  • Forced Vital Capacity (FVC): The amount of air that can be forcibly exhaled from the lungs after taking the deepest breath possible. It's an important measure of lung function in IPF trials.
  • DLCO (Diffusing Capacity of the Lungs for Carbon Monoxide): A test that measures how well oxygen passes from the air sacs of the lungs into the bloodstream. It's used to evaluate lung function in IPF trials.
  • UCSD SOBQ (University of California-San Diego Shortness of Breath Questionnaire): A patient-reported outcome measure used to assess the severity of shortness of breath during specific activities. It's used in IPF clinical trials to measure symptomatic improvement.
  • Pathologic Complete Response (pathCR): The absence of all cancer cells in tissue samples taken after treatment. It's an important endpoint in some cancer clinical trials.
  • RECIST (Response Evaluation Criteria in Solid Tumors): A standard way to measure how well a cancer patient responds to treatment. It's based on whether tumors shrink, stay the same, or get bigger.

References

  1. https://clinicaltrials.gov/study/NCT01226485
  2. https://clinicaltrials.gov/study/NCT01681186
  3. https://clinicaltrials.gov/study/NCT01919398
  4. https://clinicaltrials.gov/study/NCT05199584
  5. https://clinicaltrials.gov/study/NCT01697514
  6. https://clinicaltrials.gov/study/NCT01722292
  7. https://clinicaltrials.gov/study/NCT02530437
  8. https://clinicaltrials.gov/study/NCT04968574
  9. https://clinicaltrials.gov/study/NCT01746745
  10. https://clinicaltrials.gov/study/NCT05817240
  11. https://clinicaltrials.gov/study/NCT02784795